Clinical Trial Update: ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

View source ↗

Summary

This is an Italian multicenter, prospective observational study evaluating Ofatumumab in Relapsing-Remitting multiple sclerosis, sponsored by Novartis. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: ACTIVE_NOT_RECRUITING